Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction

H. Joachim Deeg

doi:10.1007/bf02982546

journal article Jul 01, 2001

Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction

H. Joachim Deeg

International Journal of Hematology Vol. 74 No. 1 pp. 26-32 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf02982546

Topics

No keywords indexed for this article. Browse by subject →

References

71

[1]

Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease [review].Biol Blood Marrow Transplant. 1999;5:347–356. 10.1016/s1083-8791(99)70011-x

[2]

Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.J Clin Invest. 1999;104:459–467. 10.1172/jci6896

[3]

Xun CQ,Tsuchida M,Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation.Transplantation. 1997;64:297–302. 10.1097/00007890-199707270-00021

[4]

Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.Blood. 1997;90:3204–3213. 10.1182/blood.v90.8.3204

[5]

Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review].Blood. 2000;95:2754–2759. 10.1182/blood.v95.9.2754.009k25_2754_2759

[6]

Janossy G, Bofill M, Poulter LW, et al. Separate ontogeny of two macrophage-like accessory cell populations in the human fetus.J Immunol. 1986;136:4354–4361. 10.4049/jimmunol.136.12.4354

[7]

Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells.Science. 1999;285:412–415. 10.1126/science.285.5426.412

[8]

Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.Blood. 1998;91:4051–4055. 10.1182/blood.v91.11.4051

[9]

Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.Proc Natl Acad Sci U S A. 1997;94:1366–1371. 10.1073/pnas.94.4.1366

[10]

Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.J Clin Invest. 1997;100:904–911. 10.1172/jci119606

[11]

Hiroyasu S, Shiraishi M, Koji T, et al. Analysis of Fas system in pulmonary injury of graft-versus-host disease after rat intestinal transplantation.Transplantation. 1999;68:933–938. 10.1097/00007890-199910150-00006

[12]

Lesnikova M, Lesnikov V, Arrighi S, Kistler G, Pierpaoli W, Deeg HJ. Upregulation of interleukin-10 and inhibition of alloantigen responses by transferrin and transferrin-derived glycans.J Hematother Stem Cell Res. 2000;9:381–392. 10.1089/15258160050079498

[13]

Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.J Immunol. 1999;162:4373–4376. 10.4049/jimmunol.162.8.4373

[14]

Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.J Immunol. 1998;160:4225–4231. 10.4049/jimmunol.160.9.4225

[15]

Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.Blood. 2000;95:2434–2439. 10.1182/blood.v95.7.2434

[16]

Schultz KR, Paquet J, Bader S, Hayglass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.Bone Marrow Transplant. 1995;16:289–295.

[17]

Schwaighofer H, Oberhuber G, Hebart H, et al. Endogenous inter-leukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.Transplantation. 1997;63:52–56. 10.1097/00007890-199701150-00010

[18]

Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.Blood. 1994;84:1342–1348. 10.1182/blood.v84.4.1342.1342

[19]

Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation.Transplantation. 1999;67:1478–1480. 10.1097/00007890-199906150-00015

[20]

Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd Edition Revised and Expanded. New York, NY: Marcel Dekker, Inc., 1997:257–290.

[21]

Kozlowski T, Sablinski T, Basker M, et al. Decreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatment.Bone Marrow Transplant. 2000;25:47–52. 10.1038/sj.bmt.1702083

[22]

Jadus MR, Websic HT. The role of cytokines in graft-versus-host reactions and disease.Bone Marrow Transplant. 1992;10:1–14.

[23]

Clancy JJ, Goral J, Kovacs EJ, Ellis T. Role of recombinant inter-leukin-2 (rIL-2) and large granular lymphocytes (LGLs) in acute rat graft-versus-host disease (GVHD).Transplant Proc. 1989;21:88–89.

[24]

Hervé P, Wijdenes J, Bergerat JP, Milpied N, Gaud C, Bordigoni P. Treatment of acute graft-versus-host disease with monoclonal antibody to IL-2 receptor.Lancet. 1988;2:1072–1073. 10.1016/s0140-6736(88)90085-2

[25]

Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.Transplantation. 1990;50:49–54. 10.1097/00007890-199007000-00010

[26]

Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.Blood. 2000;95:83–89. 10.1182/blood.v95.1.83

[27]

Lankford KV, Mosunjac M, Hillyer CD. Effects of UVB radiation on cytokine generation, cell adhesion molecules, and cell activation markers in T-lymphocytes and peripheral blood HPCs.Transfusion. 2000;40:361–367. 10.1046/j.1537-2995.2000.40030361.x

[28]

Uharek L, Glass B, Zeis M, et al. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).Exp Hematol. 1998;26:93–99.

[29]

Klingemann H-G, Eaves CJ, Barnett MJ, et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by inter-leukin-2 administration.Bone Marrow Transplant. 1994;14:389.

[30]

Meehan KR, Verma UN, Cahill R, et al. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.Bone Marrow Transplant. 1997;20:643–651. 10.1038/sj.bmt.1700954

[31]

Murphy WJ,Welniak LA,Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.J Clin Invest. 1998;102:1742–1748. 10.1172/jci3906

[32]

Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells

Werner Krenger, Simona Rossi, Luca Piali et al.

Blood 2000 10.1182/blood.v96.1.347

[33]

Nawa Y, Teshima T, Sunami K, et al. G-CSF reduces IFN-gamma and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function.Bone Marrow Transplant. 2000;25:1035–1040. 10.1038/sj.bmt.1702402

[34]

King C, Mueller HR, Malo CM, et al. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cyto-toxic CD8+ T-cell responses.Nat Med. 2001;7:206–214. 10.1038/84659

[35]

Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.J Clin Invest. 2000;105:1289–1298. 10.1172/jci7894

[36]

del Rosario ML, Zucali JR, Kao KJ. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor.Blood. 1999;93:3558–3564. 10.1182/blood.v93.10.3558.410k31_3558_3564

[37]

Imoto S, Oomoto Y, Murata K, et al. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.Int J Hematol. 2000;72:92–97.

[38]

Emmanouilides CE, Luo J, Baldwin G, et al. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.Bone Marrow Transplant. 1996;18:369–375.

[39]

Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.Biol Blood Marrow Transplant. 1996;2:118–125.

[40]

Holler E, Roncarolo MG, Hintermeier-Knabe R, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation.Bone Marrow Transplant. 2000;25:237–241. 10.1038/sj.bmt.1702126

[41]

Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation.Transplantation. 1998;66:863–871. 10.1097/00007890-199810150-00009

[42]

Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.Blood. 1999;94:3941–3946. 10.1182/blood.v94.11.3941

[43]

Gorczynski RM, Chen Z, Zeng H, Gorczynski L, Terzioglu E. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.Immunology. 1998;93:221–229. 10.1046/j.1365-2567.1998.00403.x

[44]

Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.J Clin Invest. 1998;102:115–123. 10.1172/jci3132

[45]

Bozza M, Bliss JL, Maylor R, et al. Interleukin-11 reduces T-cell-dependent experimental liver injury in mice.Hepatology. 1999;30:1441–1447. 10.1002/hep.510300616

[46]

Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD [review].Leukemia & Lymphoma. 1999;33:409–420. 10.3109/10428199909058446

[47]

Glass B, Uharek L, Hartung G, et al. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.Bone Marrow Transplant. 1998;21 (suppl 3):S3-S8.

[48]

Yabe M, Yabe H, Hattori K, et al. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.Bone Marrow Transplant. 1999;24:29–34. 10.1038/sj.bmt.1701819

[49]

Kumaki S, Minegishi M, Fujie H, et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children.Int J Hematol. 1998;67:307–312. 10.1016/s0925-5710(97)00117-5

[50]

Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes.Cancer Res. 1997;57:1547–1553.

Showing 50 of 71 references

Metrics

28

Citations

71

References

Details

Published: Jul 01, 2001
Vol/Issue: 74(1)
Pages: 26-32
License: View

Authors

H

H. Joachim Deeg

Cite This Article

H. Joachim Deeg (2001). Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction. International Journal of Hematology, 74(1), 26-32. https://doi.org/10.1007/bf02982546

Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction

You May Also Like